A pivotal study published on 2018-01-01 reported the efficacy and safety of risankizumab (Skyrizi) for the treatment of moderate-to-severe plaque psoriasis. The results were from two double-blind, randomized, placebo-controlled trials, UltIMMa-1 and UltIMMa-2, and were published in The Lancet.
Background
Risankizumab (also known as risankizumab-rzaa) is a drug investigated for the treatment of moderate-to-severe chronic plaque psoriasis. This condition is a chronic autoimmune disease characterized by patches of abnormal skin.
Trial design
The published results are from two double-blind, randomized, placebo-controlled studies, UltIMMa-1 and UltIMMa-2. These studies compared risankizumab against both placebo and an active comparator, ustekinumab, in patients with moderate-to-severe chronic plaque psoriasis.
Key results
The studies demonstrated the efficacy and safety of risankizumab in patients with moderate-to-severe plaque psoriasis when compared to placebo and ustekinumab.
What this means
The publication of these pivotal trial results provides evidence supporting the use of risankizumab for moderate-to-severe plaque psoriasis. The findings, comparing risankizumab to both placebo and an active comparator, ustekinumab, contribute to the understanding of its potential role in managing this chronic condition.
Source
The information for this article is based on a pivotal publication titled 'Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-control' from PubMed, published on 2018-01-01, and available on pubmed.ncbi.nlm.nih.gov.